Literature DB >> 21836512

Update on living-donor lobar lung transplantation.

Hiroshi Date1.   

Abstract

PURPOSE OF REVIEW: Living-donor lobar lung transplantation (LDLLT) has been performed as a life-saving procedure for critically ill patients who are unlikely to survive the long wait for cadaveric lungs. This article will review the current status of LDLLT. RECENT
FINDINGS: As of 2011, LDLLT has been performed in approximately 400 patients worldwide. The use of LDLLT has decreased in the USA because of the recent change by the Organ Procurement and Transplantation Network to an urgency/benefit allocation system for cadaveric donor lungs. During the past several years, reports on LDLLT have been most exclusively from Japan where the average waiting time for a cadaveric lung is more than 2 years. LDLLT has been performed various lung diseases including bronchiolitis obliterans following hematopoietic stem cell transplantation. Successful LDLLTs have been reported for patients receiving oversized as well as undersized grafts. The 5-year survival after LDLLT was 74.6% in the 2008 official report of the Japanese Society of Lung and Heart-Lung Transplantation, and it was 88.8% in the author's personal experience.
SUMMARY: LDLLT can be performed for various lung diseases and appears to provide similar or better survival than cadaveric lung transplantation. Size mismatching can be overcome to a certain extent using various surgical techniques.

Entities:  

Mesh:

Year:  2011        PMID: 21836512     DOI: 10.1097/MOT.0b013e32834a9997

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  8 in total

Review 1.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

Review 2.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

3.  Interim report of the Japanese original donor evaluation and management system: the medical consultant system.

Authors:  Tomoyuki Nakagiri; Masayoshi Inoue; Masato Minami; Yasushi Hoshikawa; Masayuki Chida; Toru Bando; Takahiro Oto; Takeshi Shiraishi; Naoya Yamasaki; Juntaro Ashikari; Yoshiki Sawa; Meinoshin Okumura
Journal:  Surg Today       Date:  2014-07       Impact factor: 2.549

Review 4.  Donation after circulatory death and lung transplantation.

Authors:  Pedro Augusto Reck Dos Santos; Paulo José Zimermann Teixeira; Daniel Messias de Moraes Neto; Marcelo Cypel
Journal:  J Bras Pneumol       Date:  2022-04-20       Impact factor: 2.800

Review 5.  Cadaveric donor lobar lung transplantation for patients on extracorporeal membrane oxygenation as bridge-to-transplant.

Authors:  Yoshiya Toyoda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-02

Review 6.  Current status and problems of lung transplantation in Japan.

Authors:  Hiroshi Date
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

7.  Morbidity and mortality of live lung donation: results from the RELIVE study.

Authors:  R D Yusen; B A Hong; E E Messersmith; B W Gillespie; B M Lopez; K L Brown; J Odim; R M Merion; M L Barr
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

8.  Live related donor lobar lung transplantation recipients surviving well over a decade: still an option in times of advanced donor management.

Authors:  Prashant N Mohite; Aron F Popov; Magdi H Yacoub; Andre R Simon
Journal:  J Cardiothorac Surg       Date:  2013-03-07       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.